Tercer Consenso Nacional de Cáncer de Ovario 2011. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México "GICOM"

Translated title of the contribution: The Third National Ovarian Cancer Consensus 2011. Grupo de Investigacion en Cancer de Ovario y Tumores Ginecologicos de Mexico "GICOM"

Dolores Gallardo-Rincón, David Cantú-de-León, Patricia Alanís-López, Miguel Ángel Álvarez-Avitia, Joel Bañuelos-Flores, Guillermo Sidney Herbert-Núñez, Luis Fernando Oñate-Ocaña, María Delia Pérez-Montiel, Amelia Rodríguez-Trejo, Eva Ruvalcaba-Limón, Alberto Serrano-Olvera, Andrea Ortega-Rojo, Patricia Cortés-Esteban, Aura Erazo-Valle, Raquel Gerson-Cwilich, Jaime De-la-Garza-Salazar, Dan Green-Renner, Eucario León-Rodríguez, Flavia Morales-Vásquez, Andrés Poveda-VelascoJosé Luis Aguilar-Ponce, Luis Felipe Alva-López, Salvador Alvarado-Aguilar, Isabel Alvarado-Cabrero, Cinthia Alejandra Aquino-Mendoza, Carlos Eduardo Aranda-Flores, Artfy Bandera-Delgado, Eduardo Barragán-Curiel, Patricia Barrón-Rodríguez, Rocío Brom-Valladares, Paula Anel Cabrera-Galeana, Germán Calderillo-Ruiz, Salvador Camacho-Gutiérrez, Daniel Capdeville-García, Jesús Cárdenas-Sánchez, Elisa Carlón-Zárate, Óscar Carrillo-Garibaldi, Gerardo Castorena-Roji, Guadalupe Cervantes-Sánchez, Jaime Alberto Coronel-Martínez, José Gregorio Chanona-Vilchis, Verónica Díaz-Hernández, Pedro Escudero-De-Los Ríos, Olga Garibay-Cerdenares, Eva Gómez-García, Luis Alonso Herrera-Montalvo, Luz María Hinojosa-García, David Isla-Ortiz, Josefina Jiménez-López, Arturo Javier Lavín-Lozano, Jesús Alberto Limón-Rodríguez, Horacio Noé López-Basave, Sergio César López-García, Antonio Maffuz-Aziz, Jorge Martínez-Cedillo, Dulce María Martínez-López, Juan Manuel Medina-Castro, Carlos Melo-Martínez, Carmen Méndez-Herrera, Gonzalo Montalvo-Esquivel, Miguel Ángel Morales-Palomares, Andrés Morán-Mendoza, Gilberto Morgan-Villela, Aída Mota-García, David Eduardo Muñoz-González, Francisco J. Ochoa-Carrillo, Maricruz Pérez-Amador, Edgar Recinos-Money, Samuel Rivera-Rivera, Juan U. Robles Flores, Edith Rojas-Castillo, Carlos Rojas-Marín, Efraín Salas-Gonzáles, Liliana Sámano-Nateras, Miguel Santibañez-Andrade, Antonio Santillán-Gómez, Araceli Silva-García, Juan Alejandro Silva, Gilberto Solorza-Luna, Adán Raúl Tabarez-Ortiz, Patricia Talamás-Rohana, Laura Leticia Tirado-Gómez, Alfonso Torres-Lobatón, Félix Quijano-Castro

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction. Ovarian cancer (OC) is the third most common gynecologic malignancy worldwide. Most of cases it is of epithelial origin. At the present time there is not a standardized screening method, which makes difficult the early diagnosis. The 5-year survival is 90% for early stages, however most cases present at advanced stages, which have a 5-year survival of only 5-20%. GICOM collaborative group, under the auspice of different institutions, have made the following consensus in order to make recommendations for the diagnosis and management regarding to this neoplasia. Material and methods. The following recommendations were made by independent professionals in the field of Gynecologic Oncology, questions and statements were based on a comprehensive and systematic review of literature. It took place in the context of a meeting of two days in which a debate was held. These statements are the conclusions reached by agreement of the participant members. Results. No screening method is recommended at the time for the detection of early lesions of ovarian cancer in general population. Staging is surgical, according to FIGO. In regards to the pre-surgery evaluation of the patient, it is recommended to perform chest radiography and CT scan of abdomen and pelvis with IV contrast. According to the histopathology of the tumor, in order to consider it as borderline, the minimum percentage of proliferative component must be 10% of tumor's surface. The recommended standardized treatment includes primary surgery for diagnosis, staging and cytoreduction, followed by adjuvant chemotherapy. Surgery must be performed by an Oncologist Gynecologist or an Oncologist Surgeon because inadequate surgery performed by another specialist has been reported in 75% of cases. In regards to surgery, it is recommended to perform total omentectomy since subclinic metastasis have been documented in 10-30% of all cases, and systematic limphadenectomy, necessary to be able to obtain an adequate surgical staging. Fertility-sparing surgery will be performed in certain cases, the procedure should include a detailed inspection of the contralateral ovary and also negative for malignancy omentum and ovary biopsy. Until now, laparoscopy for diagnostic-staging surgery is not well known as a recommended method. The recommended chemotherapy is based on platin and taxanes for 6 cycles, except in Stage IA, IB and grade 1, which have a good prognosis. In advanced stages, primary cytoreduction is recommended as initial treatment. Minimal invasion surgery is not a recommended procedure for the treatment of advanced ovarian cancer. Radiotherapy can be used to palliate symptoms. Follow up of the patients every 2-4 months for 2 years, every 3-6 months for 3 years and anually after the 5th year is recommended. Evaluation of quality of life of the patient must be done periodically. Conclusions. In the present, there is not a standardized screening method. Diagnosis in early stages means a better survival. Standardized treatment includes primary surgery with the objective to perform an optimal cytoreduction followed by chemotherapy. Treatment must be individualized according to each patient. Radiotherapy can be indicated to palliate symptoms.

Translated title of the contributionThe Third National Ovarian Cancer Consensus 2011. Grupo de Investigacion en Cancer de Ovario y Tumores Ginecologicos de Mexico "GICOM"
Original languageSpanish
Pages (from-to)665-702
Number of pages38
JournalRevista de Investigacion Clinica
Volume63
Issue number6
StatePublished - Nov 2011

Keywords

  • Cancer
  • Chemotherapy
  • Ovarian
  • Radiotherapy
  • Surgery

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'The Third National Ovarian Cancer Consensus 2011. Grupo de Investigacion en Cancer de Ovario y Tumores Ginecologicos de Mexico "GICOM"'. Together they form a unique fingerprint.

Cite this